

Amendments to the Claims

1. (Cancelled).
2. (Cancelled).
3. (Cancelled).
4. (Cancelled).
5. (Cancelled).
6. (Cancelled).
7. (Cancelled).
8. (Cancelled).
9. (Cancelled).
10. (Cancelled).
11. (Cancelled).
12. (Cancelled).
13. (Cancelled).
14. (Cancelled).
15. (Cancelled).
16. (Cancelled).
17. (Cancelled).
18. (Cancelled).
19. (Cancelled).
20. (Cancelled).

21. (Cancelled).
22. (Cancelled).
23. (Cancelled).
24. (Cancelled).
25. (Cancelled).
26. (Cancelled).
27. (Cancelled).
28. (Currently amended) A peptide ~~comprising~~ consisting of a sequence of 8 to ~~35~~ 14 amino acids which corresponds to SEQ ID NO: 45 ~~a partial sequence from the non-structural protein region of FMDV~~, wherein said peptide has been selected through immunoreactivity with FMDV-specific antibodies or through immunoreactivity with FMDV-specific T lymphocytes.
29. (Currently amended) A peptide ~~comprising~~ consisting of a polypeptide sequence ~~selected from the group consisting of SEQ ID NO. 1 to 15, 23 to 43, and 45 to 48.~~
30. (Currently amended) A method for detecting FMDV infected animals comprising ~~detecting immunoreactivity against a peptide comprising a polypeptide sequence selected from the group consisting of SEQ ID NO. 1 to 15, 23 to 43, and 45 to 48.~~ the steps of:
isolating serum from said animal; and
detecting the presence of FMDV antibodies specific for the peptide of SEQ ID NO: 45.
31. (Currently amended) A method for differentiating vaccinated and infected animals comprising ~~detecting immunoreactivity against a peptide comprising a polypeptide sequence selected from the group consisting of SEQ ID NO. 1 to 15, 23 to 43, and 45 to 48.~~ the steps of:
isolating lymphocytes from a vaccinated or infected animal;
co-incubating the lymphocytes with a peptide of SEQ ID NO: 45; and
detecting one or more responses consisting of lymphocyte proliferation, cytokine production, and cytolytic activity.